| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
(Rac)-BRD0705 targets glycogen synthase kinase 3 alpha (GSK3α), a key enzyme involved in glycogen metabolism and cell signaling. BRD0705 is a potent GSK3α inhibitor with an IC50 of 66 nM and a Kd of 4.8 μM. The racemate is less active.
|
|---|---|
| ln Vitro |
In vitro, (Rac)-BRD0705 is a less active racemate of BRD0705. BRD0705 is a potent, paralog selective GSK3α inhibitor with an IC50 of 66 nM. The racemate serves as a negative control in GSK3α inhibition studies.
|
| ln Vivo |
In vivo, (Rac)-BRD0705 is used as a negative control for the active enantiomer BRD0705. BRD0705 is an orally active GSK3α inhibitor. The racemate is used to distinguish specific GSK3α-mediated effects from non-specific effects in animal models.
|
| Enzyme Assay |
In vitro enzyme assays for (Rac)-BRD0705 involve measuring its inhibition of GSK3α activity. Recombinant GSK3α is incubated with increasing concentrations of the compound, ATP, and a specific peptide substrate. Phosphorylation is measured using radioactive or luminescence-based assays. IC50 values are calculated. Its activity is compared to the active enantiomer BRD0705.
|
| Cell Assay |
For in vitro cell-based assays, cells are cultured and treated with (Rac)-BRD0705 at various concentrations. GSK3α inhibition is confirmed by measuring the phosphorylation of GSK3α substrates (e.g., β-catenin) via Western blot. Cell viability is assessed by standard assays. The compound's effects are compared to the active enantiomer.
|
| Animal Protocol |
In vivo animal studies with (Rac)-BRD0705 are conducted as negative controls in models where BRD0705 is tested. The compound is administered orally to rodents. Its effects on GSK3α-mediated pathways are compared to the active enantiomer to confirm target specificity.
|
| ADME/Pharmacokinetics |
(Rac)-BRD0705 (CAS: 1597440-03-3) has a molecular weight of 321.42 g/mol and a molecular formula of C20H23N3O. Appearance: solid powder. Purity: ≥98%. Storage: -20°C. The compound is a less active racemate of BRD0705.
|
| Toxicity/Toxicokinetics |
(Rac)-BRD0705 is a research compound and is not approved for human therapeutic use. In preclinical studies, it has shown a manageable safety profile. As a GSK3α inhibitor, it may have effects on glycogen metabolism and cell signaling. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
(Rac)-BRD0705 is a less active racemate of BRD0705, a potent and orally active GSK3α inhibitor. It has the CAS number 1597440-03-3 and a molecular weight of 321.42 g/mol. It is used as a negative control in research. It is not FDA-approved and is intended for research use only.
|
| Molecular Formula |
C20H23N3O
|
|---|---|
| Molecular Weight |
321.416124582291
|
| Exact Mass |
321.184
|
| CAS # |
1597440-03-3
|
| Related CAS # |
BRD0705;2056261-41-5;BRD5648;2056261-42-6
|
| PubChem CID |
136980454
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
24
|
| Complexity |
561
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1CC(C)(C)CC2=C1C(C1C=CC=CC=1)(CC)C1C=NNC=1N2
|
| InChi Key |
NCKLQXXBRWCYMA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H23N3O/c1-4-20(13-8-6-5-7-9-13)14-12-21-23-18(14)22-15-10-19(2,3)11-16(24)17(15)20/h5-9,12H,4,10-11H2,1-3H3,(H2,21,22,23)
|
| Chemical Name |
4-ethyl-7,7-dimethyl-4-phenyl-1,6,8,9-tetrahydropyrazolo[3,4-b]quinolin-5-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~777.80 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.47 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1112 mL | 15.5560 mL | 31.1119 mL | |
| 5 mM | 0.6222 mL | 3.1112 mL | 6.2224 mL | |
| 10 mM | 0.3111 mL | 1.5556 mL | 3.1112 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
